Intech Investment Management LLC lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 21.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 99,404 shares of the company’s stock after selling 27,319 shares during the quarter. Intech Investment Management LLC’s holdings in Merck & Co., Inc. were worth $14,444,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. grew its position in Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares during the last quarter. State Street Corp increased its stake in Merck & Co., Inc. by 0.9% during the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after purchasing an additional 1,087,583 shares in the last quarter. Wellington Management Group LLP increased its stake in Merck & Co., Inc. by 2.3% during the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after purchasing an additional 1,934,312 shares in the last quarter. Fisher Asset Management LLC increased its stake in Merck & Co., Inc. by 8.3% during the 3rd quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company’s stock valued at $6,059,345,000 after purchasing an additional 3,183,169 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after purchasing an additional 2,919,780 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on MRK shares. Barclays raised their price target on shares of Merck & Co., Inc. from $150.00 to $180.00 and gave the stock an “overweight” rating in a report on Monday, October 26th. Weiss Ratings raised shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 25th. Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a research report on Wednesday, August 12th. JPMorgan Chase & Co. upped their target price on Merck & Co., Inc. from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Finally, Cantor Fitzgerald raised their target price on Merck & Co., Inc. from $145.00 to $155.00 and gave the stock a “neutral” rating in a research note on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $155.74.
Insider Buying and Selling
In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the completion of the sale, the executive vice president directly owned 112,955 shares in the company, valued at approximately $16,718,469.55. The trade was a 34.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.17% of the company’s stock.
Merck & Co., Inc. Trading Down 2.2%
Merck & Co., Inc. stock opened at $144.49 on Tuesday. The stock has a 50-day moving average price of $146.04 and a 200 day moving average price of $128.80. The company has a market capitalization of $356.20 billion, a price-to-earnings ratio of 148.96, a price-to-earnings-growth ratio of 6.74 and a beta of 0.13. Merck & Co., Inc. has a 52 week low of $92.11 and a 52 week high of $156.92. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The company had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter in the prior year, the company earned $2.58 EPS. Merck & Co., Inc.’s quarterly revenue was up 4.7% on a year-over-year basis. Sell-side analysts anticipate that Merck & Co., Inc. will post 2.82 EPS for the current year.
Merck & Co., Inc. Company Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Recommended Stories
- Five stocks we like better than Merck & Co., Inc.
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
